Oliver Cornely to Adult
This is a "connection" page, showing publications Oliver Cornely has written about Adult.
Connection Strength
0.163
-
Baseline predictors influencing the prognosis of invasive aspergillosis in adults. Mycoses. 2019 Aug; 62(8):651-658.
Score: 0.014
-
Prognostic factors in 264 adults with invasive Scedosporium spp. and Lomentospora prolificans infection reported in the literature and FungiScope®. Crit Rev Microbiol. 2019 Feb; 45(1):1-21.
Score: 0.013
-
Isavuconazole for treatment of rare invasive fungal diseases. Mycoses. 2018 Aug; 61(8):518-533.
Score: 0.013
-
How to prophylax against invasive fungal infections in adult ALL? An unmet need. Mycoses. 2018 Sep; 61(9):646-649.
Score: 0.013
-
Isavuconazole shortens the QTc interval. Mycoses. 2018 Apr; 61(4):256-260.
Score: 0.012
-
Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease. J Antimicrob Chemother. 2017 Dec 01; 72(12):3406-3413.
Score: 0.012
-
Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia. J Antimicrob Chemother. 2017 08 01; 72(8):2359-2367.
Score: 0.012
-
ECMM/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low- and middle-income countries. Mycoses. 2021 Sep; 64(9):1028-1037.
Score: 0.004
-
Analysis of IgM, IgA, and IgG isotype antibodies Directed against SARS-CoV-2 spike glycoprotein and ORF8 in the course of COVID-19. Sci Rep. 2021 04 26; 11(1):8920.
Score: 0.004
-
Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system. Med Mycol. 2020 Jun 01; 58(4):417-424.
Score: 0.004
-
Rapid response infrastructure for pandemic preparedness in a tertiary care hospital: lessons learned from the COVID-19 outbreak in Cologne, Germany, February to March 2020. Euro Surveill. 2020 05; 25(21).
Score: 0.004
-
Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn). J Antimicrob Chemother. 2019 11 01; 74(11):3315-3327.
Score: 0.004
-
Mould-reactive T cells for the diagnosis of invasive mould infection-A prospective study. Mycoses. 2019 Jul; 62(7):562-569.
Score: 0.003
-
Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials. Lancet Infect Dis. 2019 03; 19(3):265-274.
Score: 0.003
-
Food Intake Recruits Orosensory and Post-ingestive Dopaminergic Circuits to Affect Eating Desire in Humans. Cell Metab. 2019 03 05; 29(3):695-706.e4.
Score: 0.003
-
European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. J Antimicrob Chemother. 2018 12 01; 73(12):3221-3230.
Score: 0.003
-
Treatment outcomes in patients with proven/probable vs possible invasive mould disease in a phase III trial comparing isavuconazole vs voriconazole. Mycoses. 2018 Nov; 61(11):868-876.
Score: 0.003
-
Rare mould infections caused by Mucorales, Lomentospora prolificans and Fusarium, in San Diego, CA: the role of antifungal combination therapy. Int J Antimicrob Agents. 2018 Nov; 52(5):706-712.
Score: 0.003
-
Diagnosis and Management of Systemic Endemic Mycoses Causing Pulmonary Disease. Respiration. 2018; 96(3):283-301.
Score: 0.003
-
Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2018 05 26; 391(10135):2116-2127.
Score: 0.003
-
Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species. Mycoses. 2018 Jul; 61(7):485-497.
Score: 0.003
-
Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial. Mycoses. 2018 Jul; 61(7):420-429.
Score: 0.003
-
Chlorhexidine-containing dressings in the prevention of central venous catheter-related bloodstream infections: A cost and resource utilization analysis. Am J Infect Control. 2018 09; 46(9):992-997.
Score: 0.003
-
Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trial. J Antimicrob Chemother. 2018 03 01; 73(3):757-763.
Score: 0.003
-
A Comparison of Aspergillus and Mucorales PCR Testing of Different Bronchoalveolar Lavage Fluid Fractions from Patients with Suspected Invasive Pulmonary Fungal Disease. J Clin Microbiol. 2018 02; 56(2).
Score: 0.003
-
Fusarium Keratitis in Germany. J Clin Microbiol. 2017 10; 55(10):2983-2995.
Score: 0.003
-
Invasive infections due to Saprochaete and Geotrichum species: Report of 23 cases from the FungiScope Registry. Mycoses. 2017 Apr; 60(4):273-279.
Score: 0.003
-
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection. N Engl J Med. 2017 01 26; 376(4):305-317.
Score: 0.003
-
Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016 Jul; 16(7):828-837.
Score: 0.003
-
Low prevalence of human metapneumovirus and human bocavirus in adult immunocompromised high risk patients suspected to suffer from Pneumocystis pneumonia. J Infect. 2009 Mar; 58(3):227-31.
Score: 0.002